Hanmi Science has pointed to obesity management as a future growth engine for the Hanmi Group. Hanmi Science plans to select 5 types of pipelines, including a new GLP-1 obesity treatment, and operate the project under the name, 'H.O.P (Hanmi Obesity Pipeline)'.

The H.O.P project includes 5 types of treatment that include ▲'efpeglenatide', which is being developed as an economical GLP-1 obesity treatment customized for Koreans, and ▲ a 'next-generation triple agonist (LA-GLP/GIP/GCG)' that simultaneously activates GLP-1, glucagon, and GIP.

In particular, Hanmi’s LA-GLP/GIP/GCG is a candidate substance that uses the company’s next-generation independent platform technology rath